Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Sonnet BioTherapeutics is a clinical-stage biotechnology company developing innovative biologic medicines, primarily targeting oncology and neuropathy. Its proprietary F<sub>H</sub>AB platform enhances cytokine delivery and tumor targeting. The company’s pipeline includes cytokine-based therapies for cancer, chemotherapy-induced peripheral neuropathy, and diabetic peripheral neuropathy, leveraging modular, long-acting constructs to improve efficacy and safety in immune modulation and nerve regeneration.
This description was generated via AI from an annual report. Updated about 1 year ago.